摘要

Background: Acetazolamide has been investigated for treating sleep apnea in newcomers ascending to high altitude. This study aimed to assess the effect of acetazolamide on sleep apnea at high altitude, determine the optimal therapeutic dose, and compare its effectiveness in healthy trekkers and obstructive sleep apnea (OSA) patients. Methods: PubMed, Embase, Scopus, Cochrane Library, and Airiti Library databases were searched up to July 2015 for randomized controlled trials (RCTs) performed above 2500 m in lowlanders and that used acetazolamide as intervention in sleep studies. Studies including participants with medical conditions other than OSA were excluded. Results: Eight studies of 190 adults were included. In healthy participants, the pooled mean effect sizes of acetazolamide on Apnea-Hypopnea Index (AHI), percentage of periodic breathing time, and nocturnal oxygenation were 34.66 [95% confidence interval (CI) 25.01-44.30] with low heterogeneity (p = 0.7, I2 = 0%), 38.56% (95% CI 18.92-58.19%) with low heterogeneity (p = 0.24, I2 = 28%), and 4.75% (95% CI 1.35-8.15%) with high heterogeneity (p < 0.01, I2 = 87%), respectively. In OSA patients, the pooled mean effect sizes of acetazolamide on AHI and nocturnal oxygenation were 13.18 (95% CI 9.25-17.1) with low heterogeneity (p = 0.33, I2 = 0%) and 1.85% (95% CI 1.08-2.62%) with low heterogeneity (P = 0.56, I2 = 0%). Conclusions: Acetazolamide improves sleep apnea at high altitude by decreasing AHI and percentage of periodic breathing time and increasing nocturnal oxygenation. Acetazolamide is more beneficial in healthy participants than in OSA patients, and a 250 mg daily dose may be as effective as higher daily doses for healthy trekkers.

原文英語
頁(從 - 到)20-29
頁數10
期刊Therapeutic Advances in Respiratory Disease
11
發行號1
DOIs
出版狀態已發佈 - 一月 1 2017

ASJC Scopus subject areas

  • 肺和呼吸系統醫學
  • 藥學(醫學)

指紋

深入研究「The effect of acetazolamide on sleep apnea at high altitude: A systematic review and meta-analysis」主題。共同形成了獨特的指紋。

引用此